Table 1

Age, cumulative cigarette smoke consumption, and lung function data of all subjects of the study.


Healthy
SAR
IPF
COB

AGE (years)
54 +/- 7
48 +/- 14
49 +/- 15
60 +/- 8
NS/S/XS
9/8/0
10/2/3
5/4/3
1/3/14
Pack-years (PY)
49 +/- 18
18 +/- 13
15 +/- 6
40 +/- 25
FEV1 (%pred.)
105 +/- 15
93 +/- 15 (*)
82 +/- 23 (*)
72 +/- 28 (**)
FEV1/VC (%pred.)
91 +/- 10
94 +/- 6 (ns)
94 +/- 15 (ns)
69 +/- 19 (**)
RAW (kPaL-1s-1)
0.22 +/- 0.08
0.16 +/- 0.1 (ns)
0.22 +/- 0.14 (ns)
0.28 +/- 0.16 (ns)
RV % TLC
32 +/- 6
33 +/- 6 (ns)
37 +/- 12 (ns)
45 +/- 10 (**)
TGV (%pred.)
112 +/- 25
89 +/- 23 (*)
91 +/- 33 (ns)
119 +/- 34 (ns)
VC (%pred.)
118 +/- 13
102 +/- 17 (**)
86 +/- 19 (**)
103 +/- 25 (ns)
MEF75 (%pred.)
107 +/- 35
92 +/- 17 (ns)
90 +/- 45 (ns)
52 +/- 37 (**)
MEF50 (%pred.)
82 +/- 27
75 +/- 24 (ns)
71 +/- 40 (ns)
32 +/- 25 (**)
MEF25 (%pred.)
62 +/- 27
48 +/- 22 (ns)
51 +/- 27 (ns)
22 +/- 18 (**)
TL,CO (%pred.)
107 +/- 33
98 +/- 14 (ns)
82 +/- 13 (**)
92 +/- 21 (ns)

Relative values of lung function parameters are given as a percentage of predicted values (% pred., [27]). Values are presented as mean +/- SD. Healthy: healthy subjects, age 40 – 65 years, SAR: patients with sarcoidosis, IPF: patients with idiopathic pulmonary fibrosis, COB: patients with chronic obstructive bronchitis. FEV1: forced expiratory volume in one second, VC: vital capacity, Raw: airway resistance, RV: residual volume, TLC: total lung capacity, TGV: thoracic gas volume, MEF25, MEF50, MEF75: maximal expiratory flow at 25, 50 and 75% of VC, respectively, TL,CO: transfer factor of the lung for carbon monoxide; ns: not significant; *: p < 0.05; **: p < 0.01.

Möller et al. BioMagnetic Research and Technology 2006 4:4   doi:10.1186/1477-044X-4-4